Search the Newsreel

Baxter International Inc. Revenue Breakdown – NYSE:BAX

This article provides a detailed revenue breakdown for Baxter International Inc (BAX) by business segment and geographical region. As of April 6 (updated), the company's largest business segments are Infusion Therapies and Technologies and Care and Connectivity Solutions, while the United States accounts for …

Baxter International (BAX) Projected to Release Earnings on Thursday

Baxter International (BAX) is expected to announce its Q2 2026 earnings before market open on Thursday, July 30th, with analysts projecting $0.36 EPS and $2.7927 billion in revenue. The company's previous quarterly report surpassed estimates but showed a negative net margin and lower earnings …

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline

The market expects Baxter International (BAX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

Baxter International stock trades steadily as spin-off plans follow mixed 2023 results

Baxter International reported mixed 2023 financial results, with significant revenue of $14.9 billion but a net loss of $2.5 billion attributed to restructuring and portfolio changes. The company is actively working on improving operating margins and is preparing for the spin-off of its kidney-care …

Abaxx Announces Normal Course Issuer Bid and Automatic Securities Purchase Plan

TORONTO, July 22, 2026 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today …

Baxter stock trades steady as spin-off and portfolio reshaping shift focus toward margins

Baxter International's stock is reflecting a business undergoing significant transition, driven by the recent spin-off of its kidney-care division and ongoing portfolio simplification. The company is now focusing on improving margins, reducing debt, and generating cash, with detailed financial reporting highlighting its revenue, earnings, …

Baxter International stock trades steadily as core therapies support earnings and spin-off integration continues

Baxter International's stock performance reflects stable demand for its hospital and renal therapies, even as the company integrates its recent Kidney Care spin-off. The company focuses on improving operating margins, optimizing costs, and disciplined capital allocation to ensure earnings resilience, supported by its diversified …

A Conversation About Baxter’s Role in Healthcare Connectivity

This article features a Q&A with Baxter's Chris Gutmann and Athar Mirza, discussing the evolving role of connectivity in healthcare. They highlight how Baxter leverages connected medical devices to streamline workflows, improve efficiency, and enhance patient care, using infusion systems as a key example. …

Baxter International stock trades steady as spin-off of kidney care business and margin focus shape

Baxter International's stock is reflecting a company in transition after spinning off its kidney care business and prioritizing margin improvement. Following mixed results in 2023 and Q1 2024, the company is focused on streamlining its portfolio and achieving significant operating margin expansion by 2025 …

Baxter International stock trades steadily as spin-off and portfolio reshaping reshape earnings prof

Baxter International's stock performance reflects its strategic portfolio reshaping, including the 2023 spin-off of its kidney care business and a renewed focus on margin improvement and cash generation. Despite a slight revenue decrease in 2023 due to these changes, the company saw improved operating …

Baxter: The Chart Points Higher, Valuation And Growth Are Less Appealing

Baxter International (BAX) Q4 2024 earnings summary

Baxter International (BAX) exceeded its Q4 and full-year 2024 guidance, with Q4 sales from continuing operations reaching $2.75B–$2.8B and full-year sales at $10.6B–$10.64B. The company completed the sale of its Kidney Care business for $3.4B and announced leadership transitions. For 2025, Baxter expects sales …

Is Baxter International Inc (BAX) a Bargain After 3.2% Drop? GF Value Says Undervalued

Baxter International Inc (BAX) recently experienced a 3.2% stock drop, bringing its price to $22.61, which GuruFocus' GF Value™ assessment indicates could make it 34.3% undervalued compared to its intrinsic value of $34.41. Despite this undervaluation and a P/E ratio significantly below historical averages, …

Is Baxter’s Class I Respiratory Device Recall Reshaping the Investment Case for Baxter International (BAX)?

Baxter Healthcare recently initiated a voluntary FDA Class I recall of its Hillrom VOLARA System single-patient-use circuit kits due to nebulizer cup leakage issues, affecting over 10,000 units. This recall raises concerns about product quality and potential liability, adding to Baxter International's challenges following …

Baxter International Updates Segment Reporting Structure and Metrics

Baxter International (BAX) has reorganized its reporting structure into two segments: Medical Products & Therapies and Healthcare Systems & Technologies, effective for the quarter ended June 30, 2026. This change aims to improve decision-making and performance assessment. The company also provided recast financial data …

How Baxter International Inc. (BAX) Affects Rotational Strategy Timing

This article analyzes Baxter International Inc. (BAX) using AI-generated signals and multi-timeframe analysis to guide rotational strategy timing. It notes weak near-term sentiment but strong mid-term prospects within a broader weak long-term bias. The analysis provides specific trading strategies including position trading, momentum breakout, …

Supply Chain Innovation Delivers More Nimble, Efficient Solutions

Baxter is focusing on supply chain innovation to create more resilient, nimble, and efficient solutions following the COVID-19 pandemic's exposure of supply chain fragilities. Key strategies include integrating AI and machine learning for optimized operations, increasing investment in supply hubs, and instituting dynamic, end-to-end …

ABXX Forecast — Price Target — Prediction for 2027

Abaxx Technologies (ABXX) Q1 2026 earnings summary

BDR Baxter International - B1AX34 - Resultados, Dividendos, Cotação e Indicadores